Patents Assigned to PsiOxus Therapeutics Limited
-
Patent number: 11439678Abstract: The present disclosure relates to a group B adenovirus comprising a sequence of formula (I): 5?ITR-B1-BA-B2-BX-BB-BY-B3-3?ITR wherein: B1 is bond or comprises: E1A, E1B or E1A-E1B; BA comprises-E2B-L1-L2-L3-E2A-L4; B2 is a bond or comprises: E3; BX is a bond or a DNA sequence comprising: a restriction site, one or more transgenes or both; BB comprises L5; BY is a bond or a DNA sequence comprising: a restriction site, one or more transgenes or both; B3 is a bond or comprises: E4; wherein at least one of BX or BY is not a bond, pharmaceutical compositions comprising the same and use of the viruses and compositions in treatment, particularly in the treatment of cancer. The disclosure also extends to plasmids and processes employed to prepare the said viruses.Type: GrantFiled: April 30, 2018Date of Patent: September 13, 2022Assignee: PSIOXUS THERAPEUTICS LIMITEDInventors: Brian Robert Champion, Alice Claire Noel Brown, Kerry David Fisher, Tamara Nicolson
-
Patent number: 11173186Abstract: A method of treating a human patient comprising systemically administering multiple doses of a parenteral formulation of a replication capable oncolytic adenovirus of subgroup B in a single treatment cycle, wherein the total dose given in each dose is in the range of 1×1010 to 1×1014 viral particles, and wherein each dose of virus is administered over a period of 1 to 90 minutes, for example at a rate of viral particle delivery in the range of 2×1010 particles per minute to 2×1012 particles per minute. Also provided are formulations of the oncolytic adenoviruses and combination therapies of the viruses and formulations with other therapeutic agents.Type: GrantFiled: June 12, 2014Date of Patent: November 16, 2021Assignee: PSIOXUS THERAPEUTICS LIMITEDInventors: John William Beadle, Kerry Fisher, Christine Wilkinson Blanc
-
Patent number: 11155622Abstract: The present disclosure relates to a replication deficient oncolytic viral vector or replication capable oncolytic virus encoding an antibody or a binding fragment thereof to the antigen-specific T-cell receptor complex (TCR) for expression on the surface of a cancer cell, pharmaceutical compositions comprising the same, and use of any one of the same in treatment, particularly in the treatment of cancer.Type: GrantFiled: December 19, 2016Date of Patent: October 26, 2021Assignee: PSIOXUS THERAPEUTICS LIMITEDInventors: Alice Claire Noel Brown, Brian Robert Champion
-
Patent number: 11142580Abstract: An oncolytic virus (for example a replication competent virus) comprising a transgene cassette encoding an anti-CD40 antibody or binding fragment thereof, wherein the transgene cassette comprises an amino acid sequence given in SEQ ID NO: 12 or a sequence at least 95% identical thereto (such as 96, 97, 98 or 99% identical thereto), in particular a cassette of SEQ ID NO: 12; pharmaceutical compositions comprising the same, methods of preparing said oncolytic virus and compositions and use of the oncolytic virus or composition in treatment, in particular in the treatment of cancer. Also provided is the treatment of a patient population characterised as having a cancer expressing CD40, in particular a cancer over expressing CD40, with a therapy according to the present disclosure.Type: GrantFiled: June 1, 2018Date of Patent: October 12, 2021Assignee: PSIOXUS THERAPEUTICS LIMITEDInventors: Brian Champion, Alice Claire Noel Bromley, Matthieu Besneux
-
Patent number: 11000559Abstract: The present disclosure provides a replication competent oncolytic adenovirus with selectivity for cancer cells, wherein the adenovirus comprises a transgene under the control of a promoter endogenous to the virus, wherein the transgene comprises a DNA sequence encoding a B7 protein or an active fragment thereof, compositions comprising same, methods of generating the viruses, and use of the viruses and compositions in treatment, particularly in the treatment of cancer.Type: GrantFiled: April 29, 2016Date of Patent: May 11, 2021Assignee: PsiOxus Therapeutics LimitedInventors: Brian Robert Champion, Alice Claire Noel Bromley
-
Patent number: 10849945Abstract: The present disclosure provides a replication competent oncolytic adenovirus with selectivity for cancer cells, wherein the adenovirus comprises a transgene under the control of a promoter endogenous to the virus, wherein the transgene comprises a DNA sequence encoding a B7 protein or an active fragment thereof, compositions comprising same, methods of generating the viruses, and use of the viruses and compositions in treatment, particularly in the treatment of cancer.Type: GrantFiled: September 18, 2018Date of Patent: December 1, 2020Assignee: PSIOXUS THERAPEUTICS LIMITEDInventors: Brian Robert Champion, Alice Claire Noel Brown
-
Patent number: 10548929Abstract: The present disclosure provides a oncolytic adenovirus with selectivity for cancer cells, wherein the adenovirus comprises a transgene under the control of a promoter endogenous to the virus, wherein the transgene comprises a DNA sequence encoding a membrane anchored anti-CD3 antibody or a binding fragment thereof, compositions comprising same, methods of generating the viruses, and use of the viruses and compositions in treatment, particularly in the treatment of cancer.Type: GrantFiled: May 3, 2017Date of Patent: February 4, 2020Assignee: PSIOXUS THERAPEUTICS LIMITEDInventors: Brian Robert Champion, Alice Claire Noel Brown
-
Patent number: 10472648Abstract: The present disclosure relates to a method of making an adenovirus plasmid comprising a part or all of an adenovirus genome and one or more original restriction sites allowing rapid and flexible manipulation of the adenovirus genome, and methods of preparing adenovirus constructs, for example comprising a transgene. The disclosure also extends to novel intermediates employed in and generated by the method, to plasmids and shuttle vectors of the method and to adenoviruses or adenoviral vectors obtainable from the plasmid and/or method. The disclosure further relates to use of the viruses or vectors, for example obtained from a method disclosed herein, in therapy, such as use in the treatment of cancer.Type: GrantFiled: December 23, 2014Date of Patent: November 12, 2019Assignee: Psioxus Therapeutics LimitedInventors: Alice Claire Noel Brown, Tamara Nicolson
-
Patent number: 10322152Abstract: The present disclosure provides a replication competent oncolytic adenovirus with selectivity for cancer cells, wherein the adenovirus comprises a transgene under the control of a promoter endogenous to the virus, wherein the transgene comprises a DNA sequence encoding a B7 protein or an active fragment thereof, compositions comprising same, methods of generating the viruses, and use of the viruses and compositions in treatment, particularly in the treatment of cancer.Type: GrantFiled: October 31, 2017Date of Patent: June 18, 2019Assignee: PSIOXUS THERAPEUTICS LIMITEDInventors: Brian Robert Champion, Alice Claire Noel Bromley
-
Publication number: 20180369304Abstract: The present disclosure relates to a replication deficient oncolytic viral vector or replication capable oncolytic virus encoding an antibody or a binding fragment thereof to the antigen-specific T-cell receptor complex (TCR) for expression on the surface of a cancer cell, pharmaceutical compositions comprising the same, and use of any one of the same in treatment, particularly in the treatment of cancer.Type: ApplicationFiled: December 19, 2016Publication date: December 27, 2018Applicant: PSIOXUS THERAPEUTICS LIMITEDInventors: Alice Claire Noel BROWN, Brian Robert CHAMPION
-
Patent number: 10124028Abstract: The present disclosure provides a replication competent oncolytic adenovirus with selectivity for cancer cells, wherein the adenovirus comprises a transgene under the control of a promoter endogenous to the virus, wherein the transgene comprises a DNA sequence encoding a B7 protein or an active fragment thereof, compositions comprising same, methods of generating the viruses, and use of the viruses and compositions in treatment, particularly in the treatment of cancer.Type: GrantFiled: August 8, 2016Date of Patent: November 13, 2018Assignee: PSIOXUS THERAPEUTICS LIMITEDInventors: Brian Robert Champion, Alice Claire Noel Brown
-
Patent number: 10034905Abstract: The present disclosure relates to a type B adenovirus wherein E4orf4 is deleted or non-functional and generally having a DNA sequence in the E3 region, in particular viruses of formula (I), compositions containing the virus, for example pharmaceutical formulations of the virus, processes for making the viruses and the compositions and use of any one of the same in treatment, particularly in the treatment of cancer, such as colorectal cancer and ovarian cancer. 5?ITR-B1-BA-B2-BX-BB-BT-B3-3?ITR??(I).Type: GrantFiled: April 13, 2015Date of Patent: July 31, 2018Assignee: PSIOXUS THERAPEUTICS LIMITEDInventors: Leonard Charles William Seymour, Alice Claire Noel Brown, Brian Robert Champion
-
Patent number: 9987314Abstract: The present disclosure relates to a group B adenovirus comprising a sequence of formula (I): 5?ITR-B1-BAB2-BX-BB-BY-B3-3?ITR wherein: B1 is bond or comprises: E1A, E1B or E1AE1B; BA comprises: E2B-L1-L2-L3-E2A-L4; B2 is a bond or comprises: E3; BX is a bond or a DNA sequence comprising: a restriction site, one or more transgenes or both; BB comprises L5; BY is a bond or a DNA sequence comprising: a restriction site, one or more transgenes or both; B3 is a bond or comprises: E4; wherein at least one of BX or BY is not a bond, pharmaceutical compositions comprising the same and use of the viruses and compositions in treatment, particularly in the treatment of cancer. The disclosure also extends to plasmids and processes employed to prepare the said viruses.Type: GrantFiled: October 24, 2014Date of Patent: June 5, 2018Assignee: Psioxus Therapeutics LimitedInventors: Brian Robert Champion, Alice Claire Noel Brown, Kerry David Fisher, Tamara Nicolson
-
Publication number: 20170313990Abstract: A Process for the Production of Adenovirus The present disclosure relates to a continuous process for the manufacture of an adenovirus wherein the process comprises the steps: A) continuously culturing, in a vessel, mammalian cells infected with the adenovirus in the presence of media suitable for supporting the cells such that the virus replicates, wherein the cells are capable of supporting viral replication, and B) isolating from the media the virus produced from step a) wherein the isolation of virus is not subsequent to a cell lysis step, wherein viable cells for virus infection and production are maintained in the vessel at a level suitable for replicating the virus for the period of continuous manufacture, wherein the process comprises at least one media change or addition and at least one cell change or addition. The disclosure also extends to viruses populations obtained or obtainable from the method.Type: ApplicationFiled: August 27, 2015Publication date: November 2, 2017Applicant: PSIOXUS THERAPEUTICS LIMITEDInventors: Brian Robert CHAMPION, Jeetendra BHATIA, Ashvin PATEL
-
Patent number: 9234185Abstract: The present invention relates to oncolytic adenoviruses having therapeutic applications. Recombinant chimeric adenoviruses, and methods to produce them are provided. The chimeric adenoviruses of the invention comprise nucleic acid sequences derived from adenoviral serotypes classified within the subgroups B through F and demonstrate an enhanced therapeutic index.Type: GrantFiled: August 20, 2014Date of Patent: January 12, 2016Assignee: PSIOXUS THERAPEUTICS LIMITEDInventors: Paul Harden, Terry Hermiston, Irene Kuhn
-
Patent number: 9115337Abstract: The present invention relates to oncolytic adenoviruses having therapeutic applications. Recombinant chimeric adenoviruses, and methods to produce them are provided. The chimeric adenoviruses of the invention comprise nucleic acid sequences derived from adenoviral serotypes classified within the subgroups B through F and demonstrate an enhanced therapeutic index.Type: GrantFiled: March 13, 2013Date of Patent: August 25, 2015Assignee: PsiOxus Therapeutics LimitedInventors: Paul Harden, Terry Hermiston, Irene Kuhn
-
Patent number: 9034344Abstract: The present invention relates to oncolytic adenoviruses having therapeutic applications. Recombinant chimeric adenoviruses, and methods to produce them are provided. The chimeric adenoviruses of the invention comprise nucleic acid sequences derived from adenoviral serotypes classified within the subgroups B through F and demonstrate an enhanced therapeutic index.Type: GrantFiled: April 15, 2013Date of Patent: May 19, 2015Assignee: PsiOxus Therapeutics LimitedInventors: Paul Harden, Terry Hermiston, Irene Kuhn
-
Patent number: 8835485Abstract: The present invention provides a means for prevention and treatment of sarcopenia by administration of a substance that both reduces the sensibility of beta-adrenergic receptors and of 5-HT1a receptors. (S)-pindolol, (S)-propanol, tertalol, or bopindolol are preferred for this purpose.Type: GrantFiled: April 29, 2010Date of Patent: September 16, 2014Assignee: PsiOxus Therapeutics LimitedInventors: Jochen Springer, Stefan Anker, Andrew Coats, John Beadle
-
Patent number: 8815563Abstract: Modified viral particles wherein the viral particles, typically adenoviral particles, are modified by glycosylation and the use of the modified viral particles to deliver heterologous nucleic acid to cells. Also disclosed are pharmaceutical compositions comprising the same and method of treatment using the same.Type: GrantFiled: July 18, 2005Date of Patent: August 26, 2014Assignee: PsiOxus Therapeutics LimitedInventors: Benjamin Guy Davis, Leonard William Seymour, Kerry Fisher
-
Patent number: 8765463Abstract: The present invention relates to oncolytic adenoviruses having therapeutic applications. Recombinant chimeric adenoviruses, and methods to produce them are provided. The chimeric adenoviruses of the invention comprise nucleic acid sequences derived from adenoviral serotypes classified within the subgroups B through F and demonstrate an enhanced therapeutic index.Type: GrantFiled: April 10, 2012Date of Patent: July 1, 2014Assignee: PsiOxus Therapeutics LimitedInventors: Paul Harden, Terry Hermiston, Irene Kuhn